Blog - Announcements

Vasomedical Announces Appointment of Joshua Markowitz as Chairman of the Board

Mr. Simon Srybnik is named Chairman Emeritus

PLAINVIEW, NY / ACCESSWIRE / August 22, 2016 / Vasomedical, Inc. (“Vasomedical”) (OTC PK: VASO) today announced the appointment of Mr. Joshua Markowitz as Chairman of the Board of Directors of the Company, effective August 19, 2016. An investor in various areas including healthcare, Mr. Markowitz has served as a director of the Company since June 2015. He has been a practicing attorney for more than thirty years in the State of New Jersey and is a senior partner in the firm Markowitz O’Donnell LLC.

Concurrently, Mr. Simon Srybnik has resigned as a director and as Chairman of Vasomedical. The Board of Directors of Company has named Mr. Srybnik Chairman Emeritus in gratitude for his long and faithful service to the Company as well as his significant contributions to the growth and success of the Company.

“It was Simon’s investment nine years ago as well as his continued involvement in Vasomedical that changed the Company’s history, and we are so fortunate and grateful to have had his vision, his wisdom, his leadership, and his friendship,” stated Jun Ma, President and Chief Executive Office of Vasomedical. “We will continue our journey of diversification and growth under the leadership of Mr. Markowitz and are confident in our strategy going forward.”

“Since I joined the board more than a year ago, I have had the privilege to participate in many decisions by the Company and have also observed first hand the performance of the management team,” commented Joshua Markowitz upon his appointment as Chairman of the Board of Directors. “I am honored, and humbled, by the opportunity and I look forward to working with the outstanding professionals at Vasomedical to bring Simon’s vision for the Company to its full fruition.”

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company with several distinctive but related specialties: professional sales services for diagnostic imaging products; managed IT systems and services, including healthcare software solutions and network connectivity services; and design, manufacture and sale of proprietary medical devices.

Vasomedical operates through four wholly owned subsidiaries. Vaso Diagnostics, Inc. d.b.a. VasoHealthcare (, provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments in the USA. Vaso Technology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of GE Healthcare IT’s Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support, and NetWolves Network Services LLC (, a managed network services provider with an extensive, proprietary service platform to a broad base of customers. Vasomedical Solutions, Inc. (, manages and coordinates the design, manufacture and sales of EECP® Therapy Systems and other medical equipment operations. Vasomedical Global Corp. (, operates the Company’s China-based subsidiaries, including Biox Instruments Co. Ltd. and Life Enhancement Technology Limited. It is also the minority shareholder of VSK Medical Limited, a marketing and sales company for ECP products in the international market. Additional information is available on the Company’s website at

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “feel”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreements; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Link to Yahoo Finance: